There’s a popular young-donor plasma therapy that costs $8,000, but the FDA’s stance on the issue is conflicted, to say the least. The startup is led by Jesse Karmazin, who vividly described the method in an interview with CBS Philadelphia in December 2018. “Their brains are younger, their hearts. Their hair, if it was gray, it turns dark again,” he said of experiments run on elderly rats.
Karmazin earned his medical degree at Stanford but never obtained a license to practice and his startup Ambrosia has already sold the treatment to eager patients. For $8,000, you could get a liter of plasma, while two liters cost $12,000. Every donor was between 16 and 25, so some of that plasma came from teenagers. Ambrosia, as of the latest reporting, saw patients in five cities, and payment was usually handled online.
